Ticagrelor
- Generic Name
- Ticagrelor
- Brand Names
- Brilinta, Brilique
- Drug Type
- Small Molecule
- Chemical Formula
- C23H28F2N6O4S
- CAS Number
- 274693-27-5
- Unique Ingredient Identifier
- GLH0314RVC
- Background
Ticagrelor, or AZD6140, was first described in the literature in 2003. Ticagrelor is an ADP derivative developed for its P2Y receptor antagonism. Unlike clopidogrel, ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,.
Ticagrelor was granted EMA approval on 3 December 2010.
Ticagrelor was granted FDA approval on 20 July 2011.
- Indication
Ticagrelor is indicated to reduce the risk of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome or a history of myocardial infarction. Ticagrelor is also indicated to reduce the risk of a first myocardial infarction or stroke in high risk patients with coronary artery disease.
- Associated Conditions
- Cardiovascular Mortality, Myocardial Infarction, Stroke, Thrombosis (Stent Thrombosis)
Paclitaxel-Coated Balloon Versus Zotarolimus-Eluting Stent for Treatment of De Novo Coronary Artery Lesions
- Conditions
- De Novo StenosisCoronary Artery DiseasePercutaneous Coronary Intervention
- Interventions
- Device: Lepu Paclitaxel coated balloonDevice: Resolute Integrity Zotarolimus eluting stents
- First Posted Date
- 2022-01-26
- Last Posted Date
- 2024-01-24
- Lead Sponsor
- Xijing Hospital
- Target Recruit Count
- 370
- Registration Number
- NCT05209412
- Locations
- 🇨🇳
Ling Tao, Xi'an, Shannxi, China
Switching From Ticagrelor to Prasugrel in Patients With Acute Coronary Syndrome
- Conditions
- Acute Coronary Syndrome
- Interventions
- First Posted Date
- 2022-01-10
- Last Posted Date
- 2022-03-17
- Lead Sponsor
- Vastra Gotaland Region
- Target Recruit Count
- 16000
- Registration Number
- NCT05183178
- Locations
- 🇸🇪
Dep. Cardiology, Skånes universitetssjukhus, Lund, Sweden
Dual Antiplatelet Therapy in Patients With Clopidogrel Resistance Following Off-Pump Coronary Artery Bypass
- First Posted Date
- 2021-12-22
- Last Posted Date
- 2021-12-22
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 204
- Registration Number
- NCT05166538
- Locations
- 🇰🇷
Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of
Ticagrelor Monotherapy After Stenting
- First Posted Date
- 2021-12-08
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Vastra Gotaland Region
- Target Recruit Count
- 200
- Registration Number
- NCT05149560
- Locations
- 🇸🇪
Kardiologen, Gothenburg, Sweden
Differential EFfects of Dual antIplatelet and Dual aNtithrombotic thErapy on Hemostasis in Chronic Coronary Syndrome Patients
- Conditions
- ThrombosisMyocardial Infarction
- Interventions
- First Posted Date
- 2021-11-11
- Last Posted Date
- 2023-09-22
- Lead Sponsor
- Nova Scotia Health Authority
- Target Recruit Count
- 30
- Registration Number
- NCT05116995
- Locations
- 🇨🇦
Nova Scotia Health, Halifax, Nova Scotia, Canada
A Study to Evaluate BMS-986141 Added on to Aspirin or Ticagrelor or the Combination, on Thrombus Formation in a Thrombosis Chamber Model in Participants With Stable Coronary Artery Disease and Healthy Participants
- Conditions
- Coronary Artery DiseaseHealthy Participants
- Interventions
- First Posted Date
- 2021-10-26
- Last Posted Date
- 2023-12-05
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 58
- Registration Number
- NCT05093790
- Locations
- 🇬🇧
Local Institution - 0001, Edinburgh, United Kingdom
Replication of the ISAR-REACT 5 Antiplatelet Trial in Healthcare Claims Data
- First Posted Date
- 2021-10-20
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 28389
- Registration Number
- NCT05086081
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Effects of P2Y12 Receptor Inhibitors on Central and Peripheral Chemoreceptors' Sensitivity
- Conditions
- Dyspnea
- Interventions
- First Posted Date
- 2021-10-15
- Last Posted Date
- 2021-10-15
- Lead Sponsor
- Wroclaw Medical University
- Target Recruit Count
- 50
- Registration Number
- NCT05080478
- Locations
- 🇵🇱
Wroclaw Medical University, Wrocław, Dolnośląskie, Poland
Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis
- Conditions
- StrokeIntracranial Arteriosclerosis
- Interventions
- Other: Risk Factor Management
- First Posted Date
- 2021-09-17
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- University of Florida
- Target Recruit Count
- 1683
- Registration Number
- NCT05047172
- Locations
- 🇺🇸
University of Alabama Hospital, Birmingham, Alabama, United States
🇺🇸University of South Alabama University Hospital, Mobile, Alabama, United States
🇺🇸St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States
Ticagrelor in Elderly Patients Undergoing Percutaneous Coronary Intervention
- Conditions
- Platelet Aggregation InhibitorsAgedPercutaneous Coronary InterventionDual Anti-Platelet Therapy
- Interventions
- First Posted Date
- 2021-08-10
- Last Posted Date
- 2021-08-10
- Lead Sponsor
- The First Affiliated Hospital of Dalian Medical University
- Target Recruit Count
- 1505
- Registration Number
- NCT04999293
- Locations
- 🇨🇳
The First Affiliated Hospital of Dalian Medical University, Dalian, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.